Do analysts prefer MBAI or STRR?

Star Equity has a consensus target price of $28.00, indicating a potential upside of 153.62%. Given Star Equity's stronger consensus rating and higher possible upside, analysts plainly believe Star Equity is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Star Equity 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Does the media prefer MBAI or STRR?

In the previous week, Star Equity had 5 more articles in the media than Check-Cap. MarketBeat recorded 9 mentions for Star Equity and 4 mentions for Check-Cap. Star Equity's average media sentiment score of 1.39 beat Check-Cap's score of 0.91 indicating that Star Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Star Equity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NTRB or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NTRB or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -448.25% -106.75% -92.74% Check-Cap N/A N/A N/A

Do analysts prefer TELA or MBAI?

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe TELA Bio is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TELA or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% Check-Cap N/A N/A N/A

Do analysts rate MBAI or NEPH?

Nephros has a consensus price target of $6.00, indicating a potential upside of 79.64%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is MBAI or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nephros 4.06% 7.66% 5.86%

Do analysts prefer MBAI or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,025.75%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Check-Cap (MBAI) Competitors

$1.39 +0.02 (+1.46%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 06/12/2026 07:31 PM Eastern

Compare

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

Should you buy Check-Cap stock or one of its competitors? MarketBeat compares Check-Cap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Check-Cap include Star Equity (STRR), Nutriband (NTRB), TELA Bio (TELA), Nephros (NEPH), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry.

How does Check-Cap compare to Star Equity?

Check-Cap (NASDAQ:MBAI) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Check-Cap has a net margin of 0.00% compared to Star Equity's net margin of -4.18%. Check-Cap's return on equity of 0.00% beat Star Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Star Equity	-4.18%	-4.04%	-2.40%

Star Equity has a consensus target price of $28.00, indicating a potential upside of 153.62%. Given Star Equity's stronger consensus rating and higher possible upside, analysts plainly believe Star Equity is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 3.8% of Star Equity shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 33.5% of Star Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Check-Cap has higher earnings, but lower revenue than Star Equity. Star Equity is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Star Equity	$172.16M	0.24	-$5.92M	-$2.63	N/A

In the previous week, Star Equity had 5 more articles in the media than Check-Cap. MarketBeat recorded 9 mentions for Star Equity and 4 mentions for Check-Cap. Star Equity's average media sentiment score of 1.39 beat Check-Cap's score of 0.91 indicating that Star Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Star Equity	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Star Equity has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Summary

Star Equity beats Check-Cap on 10 of the 16 factors compared between the two stocks.

How does Check-Cap compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-106.75%	-92.74%
Check-Cap	N/A	N/A	N/A

In the previous week, Check-Cap had 2 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Check-Cap and 2 mentions for Nutriband. Check-Cap's average media sentiment score of 0.91 beat Nutriband's score of 0.47 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Nutriband	Neutral
Check-Cap	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nutriband has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	20.21	-$8.23M	-$2.60	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 0.5% of Check-Cap shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Check-Cap beats Nutriband on 7 of the 13 factors compared between the two stocks.

How does Check-Cap compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, Check-Cap had 3 more articles in the media than TELA Bio. MarketBeat recorded 4 mentions for Check-Cap and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.87 beat Check-Cap's score of 0.91 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
Check-Cap	Positive

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Check-Cap has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.48	-$38.83M	-$0.79	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe TELA Bio is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Check-Cap	N/A	N/A	N/A

Summary

TELA Bio beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Nephros?

Check-Cap (NASDAQ:MBAI) and Nephros (NASDAQ:NEPH) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Nephros has a consensus price target of $6.00, indicating a potential upside of 79.64%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Check-Cap had 3 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Check-Cap and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Check-Cap's score of 0.91 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Check-Cap	Positive
Nephros	Very Positive

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nephros	4.06%	7.66%	5.86%

Check-Cap has higher earnings, but lower revenue than Nephros. Check-Cap is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nephros	$18.79M	1.93	$1.19M	$0.07	47.71

Check-Cap has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Summary

Nephros beats Check-Cap on 13 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Plus Therapeutics?

Check-Cap (NASDAQ:MBAI) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,025.75%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

In the previous week, Plus Therapeutics had 7 more articles in the media than Check-Cap. MarketBeat recorded 11 mentions for Plus Therapeutics and 4 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.91 beat Plus Therapeutics' score of -0.68 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Positive
Plus Therapeutics	Negative

Check-Cap has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Plus Therapeutics	$5.21M	6.62	-$22.39M	-$2.30	N/A

Check-Cap has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Check-Cap's return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Plus Therapeutics	-230.24%	-198.48%	-73.13%

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Plus Therapeutics beats Check-Cap on 9 of the 15 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$9.99M	$2.81B	$4.94B	$12.02B
Dividend Yield	N/A	N/A	9.91%	5.61%
P/E Ratio	-0.50	12.29	22.22	24.43
Price / Sales	N/A	334.02	164.60	109.73
Price / Cash	2.41	8.13	42.20	55.64
Price / Book	2.96	5.47	27.17	6.79
Net Income	$4.14M	$7.39M	$118.48M	$337.66M
7 Day Performance	0.72%	-1.57%	0.64%	2.57%
1 Month Performance	-30.50%	-3.66%	-0.92%	2.04%
1 Year Performance	N/A	4.32%	13.98%	30.28%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.7528 of 5 stars	$1.39 +1.5%	N/A	N/A	$9.99M	N/A	N/A	80	Short Interest Decrease Gap Down
STRR Star Equity	4.476 of 5 stars	$11.56 -0.3%	$28.00 +142.2%	+441.2%	$42.77M	$172.16M	N/A	1,200	Positive News Insider Trade
NTRB Nutriband	0.6188 of 5 stars	$3.49 -1.8%	N/A	-55.4%	$42.38M	$2.04M	N/A	10	Earnings Report
TELA TELA Bio	3.6933 of 5 stars	$0.88 -3.0%	$2.20 +149.2%	-53.5%	$40.20M	$80.28M	N/A	120
NEPH Nephros	2.5629 of 5 stars	$3.63 -4.5%	$6.00 +65.3%	-16.7%	$39.42M	$18.79M	51.86	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

How does Check-Cap compare to Star Equity?

Summary

How does Check-Cap compare to Nutriband?

Summary

How does Check-Cap compare to TELA Bio?

Summary

How does Check-Cap compare to Nephros?

Summary

How does Check-Cap compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Check-Cap (MBAI) Competitors

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

How does Check-Cap compare to Star Equity?

Is MBAI or STRR more profitable?

Do analysts prefer MBAI or STRR?

Do institutionals & insiders have more ownership in MBAI or STRR?

Which has higher valuation & earnings, MBAI or STRR?

Does the media prefer MBAI or STRR?

Which has more risk and volatility, MBAI or STRR?

Summary

How does Check-Cap compare to Nutriband?

Is NTRB or MBAI more profitable?

Does the media refer more to NTRB or MBAI?

Do analysts prefer NTRB or MBAI?

Which has more risk & volatility, NTRB or MBAI?

Which has better earnings & valuation, NTRB or MBAI?

Do institutionals & insiders believe in NTRB or MBAI?

Summary

How does Check-Cap compare to TELA Bio?

Does the media prefer TELA or MBAI?

Do insiders and institutionals have more ownership in TELA or MBAI?

Which has better valuation and earnings, TELA or MBAI?

Do analysts prefer TELA or MBAI?

Which has more risk and volatility, TELA or MBAI?

Is TELA or MBAI more profitable?

Summary

How does Check-Cap compare to Nephros?

Do analysts rate MBAI or NEPH?

Do institutionals & insiders believe in MBAI or NEPH?

Does the media prefer MBAI or NEPH?

Is MBAI or NEPH more profitable?

Which has preferable earnings and valuation, MBAI or NEPH?

Which has more volatility and risk, MBAI or NEPH?

Summary

How does Check-Cap compare to Plus Therapeutics?

Do analysts prefer MBAI or PSTV?

Which has more volatility & risk, MBAI or PSTV?

Does the media prefer MBAI or PSTV?

Which has higher valuation and earnings, MBAI or PSTV?

Is MBAI or PSTV more profitable?

Do insiders & institutionals believe in MBAI or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools